Immorta Bio’s mission and technologies aim to leverage your young stem cells and your enhanced immune cells to deal with cancers or diseases of aging the way your body dealt with them when you were young and healthy.
Our Mission"Company files patent for treatment of chemotherapy-induced accelerated aging as a step towards treatment of other causes of aging."
"A recent publication in the prestigious scientific journal Nature Communications strongly confirmed the fundamental role of senescent cells in cancer progression"
"How understanding and manipulating senescence dynamics could optimize cancer therapies and improve patient outcomes"
Dr. Thomas Ichim, president and chief scientific officer at Immorta Bio, spoke with Pharmaceutical Executive about his company’s work focused on age related diseases and the unique challenges this brings.
Aging is the ultimate risk factor for many diseases, marked by progressive deterioration of organs and tissues and an enhanced risk of disease initiation and progression including cancer, cardiovascular disease, metabolic disorders and neurodegeneration. Conventional treatments for diseases associated with aging often provide only symptomatic relief and fail to address the underlying causes of aging.
Existing stem-cell based solutions have limitations, ranging from the absence of personalized sources of "young" cells capable of replacing aging or senescent cells in various, affected organs to largely targeting only one physiological pathway or molecule. Treating aging itself, rather than just the diseases it causes, offers a comprehensive approach to improving health outcomes, increasing longevity, and extending lifespan.
Rejuvenating Damaged Organs Utilizing Autologous stem Cells
The StemCell Revivify™ platform leverages autologous, de-differentiated “immortal” stem cells. These stem cells can be differentiated into young cells in unlimited quantities. When introduced into damaged or aged organs, they rejuvenate surrounding cells, as well as the whole organ itself. This technology applies to multiple indications, from organ failure to sepsis.
Learn MoreSenolytic immunotherapy designed to eliminate tumor promoting senescent cells
The SenoVax™ platform, generated from the patient’s blood and skin punch biopsy, consists of precision targeted immune cells that enhance the body’s innate ability to self-heal. SenoVax™ is applicable to multiple cancers as well as to organ rejuvenation.
Learn MoreAt Immorta Bio, we maintain exclusive marketing rights for our innovative therapeutic programs and are currently raising funds to advance clinical trials, upgrade lab facilities, and support ongoing research and development for our rejuvenation programs. We seek strategic partnerships to maximize their commercial potential, typically after reaching the proof-of-efficacy stage. Contact us to explore collaboration opportunities.
Immorta Bio embodies a team-centric ethos, comprising highly devoted and skilled individuals. Our collaborative teams operate synergistically within a dynamic, enjoyable, and creatively fulfilling environment. Upholding principles of high integrity, mutual respect, teamwork, open-mindedness, and scientific excellence, we prioritize recruiting, developing, and retaining individuals possessing the determination and expertise essential for success.
We provide compelling career opportunities for individuals passionate about life extension and dedicated to supporting advancements in the biotechnology field.
